➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Moodys
McKesson
AstraZeneca

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

LIDOSITE TOPICAL SYSTEM KIT Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Lidosite Topical System Kit, and when can generic versions of Lidosite Topical System Kit launch?

Lidosite Topical System Kit is a drug marketed by Vyteris and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in seven countries.

The generic ingredient in LIDOSITE TOPICAL SYSTEM KIT is epinephrine; lidocaine hydrochloride. There are twenty-one drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the epinephrine; lidocaine hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Lidosite Topical System Kit

Indicators of Generic Entry

< Available with Subscription >

  Free Forever Trial

Summary for LIDOSITE TOPICAL SYSTEM KIT
International Patents:8
US Patents:1
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:LIDOSITE TOPICAL SYSTEM KIT at DailyMed
Drug patent expirations by year for LIDOSITE TOPICAL SYSTEM KIT
Anatomical Therapeutic Chemical (ATC) Classes for LIDOSITE TOPICAL SYSTEM KIT
A01AD Other agents for local oral treatment
A01A STOMATOLOGICAL PREPARATIONS
A01 STOMATOLOGICAL PREPARATIONS
A Alimentary tract and metabolism
B02BC Local hemostatics
B02B VITAMIN K AND OTHER HEMOSTATICS
B02 ANTIHEMORRHAGICS
B Blood and blood forming organs
C01BB Antiarrhythmics, class Ib
C01B ANTIARRHYTHMICS, CLASS I AND III
C01 CARDIAC THERAPY
C Cardiovascular system
C01CA Adrenergic and dopaminergic agents
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01 CARDIAC THERAPY
C Cardiovascular system
C05AD Local anesthetics
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05 VASOPROTECTIVES
C Cardiovascular system
D04AB Anesthetics for topical use
D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D Dermatologicals
N01BB Amides
N01B ANESTHETICS, LOCAL
N01 ANESTHETICS
N Nervous system
R01AA Sympathomimetics, plain
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
R02AD Anesthetics, local
R02A THROAT PREPARATIONS
R02 THROAT PREPARATIONS
R Respiratory system
R03AA Alpha- and beta-adrenoreceptor agonists
R03A ADRENERGICS, INHALANTS
R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R Respiratory system
S01EA Sympathomimetics in glaucoma therapy
S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01 OPHTHALMOLOGICALS
S Sensory organs
S01HA Local anesthetics
S01H LOCAL ANESTHETICS
S01 OPHTHALMOLOGICALS
S Sensory organs
S02DA Analgesics and anesthetics
S02D OTHER OTOLOGICALS
S02 OTOLOGICALS
S Sensory organs

US Patents and Regulatory Information for LIDOSITE TOPICAL SYSTEM KIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vyteris LIDOSITE TOPICAL SYSTEM KIT epinephrine; lidocaine hydrochloride PATCH;IONTOPHORESIS, TOPICAL 021504-001 May 6, 2004 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LIDOSITE TOPICAL SYSTEM KIT

Premature patent expiration for: LIDOSITE TOPICAL SYSTEM KIT

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
⤷  Free Forever Trial LIDOSITE TOPICAL SYSTEM KIT ⤷  Free Forever Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Moodys
McKesson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.